查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586281

降胆固醇药物市场：按疾病类型、药物类别、分销管道划分 - 全球预测 2025-2030

Cholesterol Lowering Drug Market by Disease Type (Cardiovascular Diseases, Hypercholesterolemia, Hyperlipidemia), Class of Drug (Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations), Distribution Channels - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年降胆固醇药物市值为220亿美元，预计2024年将达到238亿美元，复合年增长率为8.30%，预计2030年将达到384.5亿美元。

降胆固醇药物市场是製药业的重要组成部分，重点关注旨在降低血液胆固醇水平的药物，主要针对低密度脂蛋白胆固醇，以预防心血管疾病。由于不良饮食、缺乏体力活动和老化等生活方式因素，全球范围内胆固醇相关疾病的增加凸显了对此类药物的需求。应用范围从对高风险族群的预防性治疗到对已经患有心血管疾病的人群的干预，最终用户包括医院、诊所和治疗慢性病的个人。该市场的成长主要受到高胆固醇症盛行率的增加、老年人口的扩大以及人们对心臟健康意识不断增强的影响。

主要市场统计
基准年[2023] 220亿美元
预测年份 [2024] 238亿美元
预测年份 [2030] 384.5亿美元
复合年增长率（%） 8.30%

然而，品牌药物的高成本、潜在副作用和药物依从性挑战等限制因素可能会阻碍市场扩张。此外，替代疗法和生活方式干预措施的日益普及也带来了竞争挑战。儘管存在这些障碍，潜在的机会在于新型生技药品和生物仿製药的开发、个人化医疗方法以及医疗保健可及性不断改善的新兴市场的扩张。为了抓住这些机会，鼓励製药公司投资下一代降胆固醇药物的研发，并利用资料分析来制定个人化治疗计画。

创新可以集中于解决多种心血管危险因素的联合治疗和支持患者监测和依从性的数位健康技术。基因疗法和营养食品的研究也有望成为突破性的治疗方法。在未满足的医疗需求和技术进步的推动下，市场竞争激烈，但充满潜力。生物技术公司和研究机构之间的联盟可以进一步加强药物发现过程，与医疗保健提供者的策略联盟可以提高患者参与度和市场渗透率。

市场动态：揭示快速发展的降胆固醇药物市场的关键市场洞察

供需的动态交互作用正在改变降胆固醇药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球低密度脂蛋白胆固醇负担增加
    • 患有胆固醇问题的老年人数量不断增加
    • 吸烟和饮酒增加会增加高胆固醇的风险
  • 市场限制因素
    • 他汀类药物的严重副作用导致横纹肌溶解症
  • 市场机会
    • 政府投资加强卫生基础设施
    • 药物配方的开发和新治疗方法的出现，包括PCSK9抑制剂的出现
  • 市场问题
    • 主要品牌学名药的可用性和严格的核准流程

波特五力：驾驭降胆固醇药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解降胆固醇药物市场的外部影响

外部宏观环境因素在塑造降胆固醇药物市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解降胆固醇药物市场的竞争格局

降胆固醇药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵降胆固醇药物市场供应商的绩效评估

FPNV定位矩阵是评估降胆固醇药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：制定降胆固醇药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对降胆固醇药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球低密度脂蛋白胆固醇负担增加
      • 患有胆固醇併发症的老年人增加
      • 吸烟和增加饮酒会增加高胆固醇的风险
    • 抑制因素
      • 他汀类药物的严重副作用导致横纹肌溶解症
    • 机会
      • 政府投资加强医疗基础设施
      • 药物组合的开发和新治疗方法的出现，例如 PCSK9 抑制剂的出现
    • 任务
      • 领先品牌学名药的可用性和严格的核准流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章降胆固醇药物市场：依疾病类型

  • 介绍
  • 心血管疾病
  • 高胆固醇症
  • 高血脂症

第七章降胆固醇药物市场：依药物类型

  • 介绍
  • 胆固醇吸收抑制剂
  • 贝特类
  • 固定剂量组合
  • 离子交换树脂
  • 新的降胆固醇药物
  • PCSK9抑制剂
  • 他汀类药物

第八章降胆固醇药物市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美降胆固醇药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区降胆固醇药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲降胆固醇药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Anant Pharmaceuticals Pvt. Ltd.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Covis Pharma GmbH
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4311CE1A338E

The Cholesterol Lowering Drug Market was valued at USD 22.00 billion in 2023, expected to reach USD 23.80 billion in 2024, and is projected to grow at a CAGR of 8.30%, to USD 38.45 billion by 2030.

The market for cholesterol-lowering drugs is a vital segment of the pharmaceutical industry, focusing on medications designed to reduce cholesterol levels in the blood, primarily targeting LDL cholesterol, to prevent cardiovascular diseases. The necessity for such drugs is underscored by the global rise in cholesterol-related conditions, driven by lifestyle factors such as poor diet, lack of exercise, and an aging population. Their application ranges from preventive treatments for at-risk individuals to interventions for those with existing cardiovascular issues, with end-users including hospitals, clinics, and individuals managing chronic conditions. Growth in this market is primarily influenced by the increasing prevalence of hypercholesterolemia, an expanding geriatric population, and heightened awareness of heart health.

KEY MARKET STATISTICS
Base Year [2023] USD 22.00 billion
Estimated Year [2024] USD 23.80 billion
Forecast Year [2030] USD 38.45 billion
CAGR (%) 8.30%

However, limitations such as high costs of branded medications, potential side effects, and medication adherence challenges can hinder market expansion. Moreover, the growing popularity of alternative therapies and lifestyle-based interventions presents a competitive challenge. Despite these obstacles, potential opportunities lie in the development of novel biologics and biosimilars, personalized medicine approaches, and expanding markets in emerging economies where healthcare access is improving. To seize these opportunities, pharmaceutical companies are advised to invest in R&D for next-generation cholesterol-lowering agents and leverage data analytics to develop personalized treatment plans.

Innovation could focus on combination therapies that address multiple cardiovascular risk factors, as well as digital health technologies that assist in patient monitoring and adherence. Research into gene therapy and nutraceuticals also offers promising avenues for breakthrough treatments. The nature of the market is increasingly competitive yet ripe with potential, driven by unmet medical needs and technological advancements. Collaborations between biotech firms and research institutions could further enhance drug discovery processes, while strategic alliances with healthcare providers could improve patient engagement and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cholesterol Lowering Drug Market

The Cholesterol Lowering Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising burden of LDL cholesterol across the globe
    • Growing geriatric population with cholesterol complications
    • Increase in smoking and alcohol consumption escalate the risk of high cholesterol
  • Market Restraints
    • Severe side effects of statins causing rhabdomyolysis
  • Market Opportunities
    • Government investment toward the strengthening healthcare infrastructure
    • Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
  • Market Challenges
    • Availability of generic drugs of leading brands and stringent approvals process

Porter's Five Forces: A Strategic Tool for Navigating the Cholesterol Lowering Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cholesterol Lowering Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cholesterol Lowering Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cholesterol Lowering Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cholesterol Lowering Drug Market

A detailed market share analysis in the Cholesterol Lowering Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cholesterol Lowering Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cholesterol Lowering Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cholesterol Lowering Drug Market

A strategic analysis of the Cholesterol Lowering Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cholesterol Lowering Drug Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Covis Pharma GmbH, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Kowa Company, Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cholesterol Lowering Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia.
  • Based on Class of Drug, market is studied across Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins.
  • Based on Distribution Channels, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of LDL cholesterol across the globe
      • 5.1.1.2. Growing geriatric population with cholesterol complications
      • 5.1.1.3. Increase in smoking and alcohol consumption escalate the risk of high cholesterol
    • 5.1.2. Restraints
      • 5.1.2.1. Severe side effects of statins causing rhabdomyolysis
    • 5.1.3. Opportunities
      • 5.1.3.1. Government investment toward the strengthening healthcare infrastructure
      • 5.1.3.2. Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of generic drugs of leading brands and stringent approvals process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cholesterol Lowering Drug Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
  • 6.3. Hypercholesterolemia
  • 6.4. Hyperlipidemia

7. Cholesterol Lowering Drug Market, by Class of Drug

  • 7.1. Introduction
  • 7.2. Cholesterol Absorption Inhibitors
  • 7.3. Fibrates
  • 7.4. Fixed-Dose Combinations
  • 7.5. Ion Exchange Resins
  • 7.6. Novel Cholesterol-Lowering Drugs
  • 7.7. PCSK9 Inhibitors
  • 7.8. Statins

8. Cholesterol Lowering Drug Market, by Distribution Channels

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Cholesterol Lowering Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cholesterol Lowering Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cholesterol Lowering Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Anant Pharmaceuticals Pvt. Ltd.
  • 3. AstraZeneca PLC
  • 4. Bristol-Myers Squibb Company
  • 5. Covis Pharma GmbH
  • 6. Daiichi Sankyo Co., Ltd.
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Kowa Company, Ltd.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Sanofi
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. CHOLESTEROL LOWERING DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. CHOLESTEROL LOWERING DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHOLESTEROL LOWERING DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHOLESTEROL LOWERING DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CHOLESTEROL ABSORPTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY NOVEL CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 150. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023